Targeting absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosine-related protein 2 (TRP-2), glycoprotein 100 (gp100), HER-2, and interleukin 13 receptor a2 (IL- 13Ra2) and previous phase 2 data140 of ICT-107 for newly diagnosed GBM also was promising. This evidence concerns the gene AIM2 and glioblastoma.